

Michael B Chancellor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2145991/publications.pdf>

Version: 2024-02-01

256
papers

11,036
citations

18482

62
h-index

38395

95
g-index

272
all docs

272
docs citations

272
times ranked

5462
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial. <i>Journal of Urology</i> , 2010, 184, 2416-2422.	0.4	352
2	Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. <i>Urology</i> , 2004, 64, 871-875.	1.0	255
3	Rapid detection of novel coronavirus/Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by reverse transcription-loop-mediated isothermal amplification. <i>PLoS ONE</i> , 2020, 15, e0234682.	2.5	254
4	INTRAVESICAL BOTULINUM TOXIN A ADMINISTRATION PRODUCES ANALGESIA AGAINST ACETIC ACID INDUCED BLADDER PAIN RESPONSES IN RATS. <i>Journal of Urology</i> , 2004, 172, 1529-1532.	0.4	242
5	URETHRAL AFFERENT NERVE ACTIVITY AFFECTS THE MICTURITION REFLEX; IMPLICATION FOR THE RELATIONSHIP BETWEEN STRESS INCONTINENCE AND DETRUSOR INSTABILITY. <i>Journal of Urology</i> , 1999, 162, 204-212.	0.4	225
6	BOTULINUM TOXIN URETHRAL SPHINCTER INJECTION TO RESTORE BLADDER EMPTYING IN MEN AND WOMEN WITH VOIDING DYSFUNCTION. <i>Journal of Urology</i> , 2001, 165, 1107-1110.	0.4	202
7	Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. <i>Urology</i> , 2005, 65, 37-41.	1.0	183
8	Preliminary results of myoblast injection into the urethra and bladder wall: A possible method for the treatment of stress urinary incontinence and impaired detrusor contractility. <i>Neurourology and Urodynamics</i> , 2000, 19, 279-287.	1.5	177
9	Immunoneutralization of Nerve Growth Factor in Lumbosacral Spinal Cord Reduces Bladder Hyperreflexia in Spinal Cord Injured Rats.. <i>Journal of Urology</i> , 2002, 168, 2269-2274.	0.4	176
10	EMERGING ROLE OF BOTULINUM TOXIN IN THE MANAGEMENT OF VOIDING DYSFUNCTION. <i>Journal of Urology</i> , 2004, 171, 2128-2137.	0.4	176
11	Effect of Botulinum Toxin A on the Autonomic Nervous System of the Rat Lower Urinary Tract. <i>Journal of Urology</i> , 2003, 169, 1896-1900.	0.4	168
12	Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. <i>BJU International</i> , 2009, 104, 657-661.	2.5	166
13	Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection. <i>European Urology</i> , 2009, 56, 700-707.	1.9	163
14	Improved sphincter contractility after allogenic muscle-derived progenitor cell injection into the denervated rat urethra. <i>Urology</i> , 2003, 62, 958-963.	1.0	157
15	LONG-TERM RESULTS OF SACRAL NERVE STIMULATION (S3) FOR THE TREATMENT OF NEUROGENIC REFRACTORY URGE INCONTINENCE RELATED TO DETRUSOR HYPERREFLEXIA. <i>Journal of Urology</i> , 2000, 164, 1476-1480.	0.4	156
16	Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. <i>BJU International</i> , 2005, 95, 733-738.	2.5	153
17	Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. <i>International Urology and Nephrology</i> , 2010, 42, 629-635.	1.4	146
18	Novel Action of Botulinum Toxin on the Stromal and Epithelial Components of the Prostate Gland. <i>Journal of Urology</i> , 2006, 175, 1158-1163.	0.4	141

#	ARTICLE	IF	CITATIONS
19	THE ROLE OF BLADDER AFFERENT PATHWAYS IN BLADDER HYPERACTIVITY INDUCED BY THE INTRAVESICAL ADMINISTRATION OF NERVE GROWTH FACTOR. <i>Journal of Urology</i> , 2001, 165, 975-979.	0.4	138
20	EFFECT OF INTRAVESICAL NITRIC OXIDE THERAPY ON CYCLOPHOSPHAMIDE-INDUCED CYSTITIS. <i>Journal of Urology</i> , 1999, 162, 2211-2216.	0.4	124
21	Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. <i>BJU International</i> , 2009, 104, 1476-1481.	2.5	118
22	Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Liposomes. <i>Journal of Urology</i> , 2009, 182, 786-792.	0.4	118
23	Autologous Muscle Derived Cell Therapy for Stress Urinary Incontinence: A Prospective, Dose Ranging Study. <i>Journal of Urology</i> , 2013, 189, 595-601.	0.4	118
24	Periurethral cellular injection: Comparison of muscle-derived progenitor cells and fibroblasts with regard to efficacy and tissue contractility in an animal model of stress urinary incontinence. <i>Urology</i> , 2006, 68, 449-454.	1.0	117
25	Diabetic Cystopathy Correlates With a Long-Term Decrease in Nerve Growth Factor Levels in The Bladder and Lumbosacral Dorsal Root Ganglia. <i>Journal of Urology</i> , 2002, 168, 1259-1264.	0.4	116
26	Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. <i>Urology</i> , 2005, 66, 775-779.	1.0	114
27	Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. <i>Nature Reviews Urology</i> , 2008, 5, 319-328.	1.4	108
28	Autologous Muscle Derived Cells for Treatment of Stress Urinary Incontinence in Women. <i>Journal of Urology</i> , 2014, 192, 469-476.	0.4	108
29	Suppression of Detrusor-Sphincter Dyssynergia by Immunoneutralization of Nerve Growth Factor in Lumbosacral Spinal Cord in Spinal Cord Injured Rats. <i>Journal of Urology</i> , 2004, 171, 478-482.	0.4	107
30	Treatment of interstitial cystitis. <i>Urology</i> , 2004, 63, 85-92.	1.0	107
31	Intraurethral muscle-derived cell injections increase leak point pressure in a rat model of intrinsic sphincter deficiency. <i>Urology</i> , 2004, 63, 780-785.	1.0	107
32	Urethral closure mechanisms under sneeze-induced stress condition in rats: a new animal model for evaluation of stress urinary incontinence. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2003, 285, R356-R365.	1.8	103
33	Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. <i>BJU International</i> , 2006, 98, 1033-1037.	2.5	102
34	Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. <i>BJU International</i> , 2009, 103, 1668-1672.	2.5	101
35	PERSISTENCE AND SURVIVAL OF AUTOLOGOUS MUSCLE DERIVED CELLS VERSUS BOVINE COLLAGEN AS POTENTIAL TREATMENT OF STRESS URINARY INCONTINENCE. <i>Journal of Urology</i> , 2001, 165, 271-276.	0.4	100
36	Long-Term Patterns of Use and Treatment Failure With Anticholinergic Agents for Overactive Bladder. <i>Clinical Therapeutics</i> , 2013, 35, 1744-1751.	2.5	100

#	ARTICLE	IF	CITATIONS
37	Pilot Study of Liposome-encapsulated OnabotulinumtoxinA for Patients with Overactive Bladder: A Single-center Study. <i>European Urology</i> , 2014, 65, 1117-1124.	1.9	100
38	The other bladder syndrome: underactive bladder. <i>Reviews in Urology</i> , 2013, 15, 11-22.	0.9	100
39	HERPES SIMPLEX VIRUS MEDIATED NERVE GROWTH FACTOR EXPRESSION IN BLADDER AND AFFERENT NEURONS: POTENTIAL TREATMENT FOR DIABETIC BLADDER DYSFUNCTION. <i>Journal of Urology</i> , 2001, 165, 1748-1754.	0.4	96
40	Qualitative and Quantitative Expression Profile of Muscarinic Receptors in Human Urothelium and Detrusor. <i>Journal of Urology</i> , 2006, 176, 1673-1678.	0.4	95
41	Anticholinergics for Overactive Bladder Therapy: Central Nervous System Effects. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 167-174.	3.9	95
42	Principles of Sacral Nerve Stimulation (SNS) for the Treatment of Bladder and Urethral Sphincter Dysfunctions. <i>Neuromodulation</i> , 2000, 3, 15-26.	0.8	94
43	Gene Therapy Using Replication-Defective Herpes Simplex Virus Vectors Expressing Nerve Growth Factor in a Rat Model of Diabetic Cystopathy. <i>Diabetes</i> , 2004, 53, 2723-2730.	0.6	92
44	Pharmacotherapy for Neurogenic Detrusor Overactivity. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2006, 85, 536-545.	1.4	92
45	Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. <i>BJU International</i> , 2010, 106, 1681-1685.	2.5	92
46	Implications of diabetes mellitus in urology. <i>Urologic Clinics of North America</i> , 2003, 30, 1-12.	1.8	89
47	Urinary Chemokines as Noninvasive Predictors of Ulcerative Interstitial Cystitis. <i>Journal of Urology</i> , 2012, 187, 2243-2248.	0.4	89
48	Blood-Brain Barrier Permeation and Efflux Exclusion of Anticholinergics Used in the Treatment of Overactive Bladder. <i>Drugs and Aging</i> , 2012, 29, 259-273.	2.7	88
49	Bladder Instillation of Liposome Encapsulated OnabotulinumtoxinA Improves Overactive Bladder Symptoms: A Prospective, Multicenter, Double-Blind, Randomized Trial. <i>Journal of Urology</i> , 2014, 192, 1743-1749.	0.4	88
50	Dynamic Progression of Overactive Bladder and Urinary Incontinence Symptoms: A Systematic Review. <i>European Urology</i> , 2010, 58, 532-543.	1.9	87
51	The role of bladder-to-urethral reflexes in urinary continence mechanisms in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 287, F434-F441.	2.7	86
52	Intraprostatic Botulinum Toxin A Injection Inhibits Cyclooxygenase-2 Expression and Suppresses Prostatic Pain on Capsaicin Induced Prostatitis Model in Rat. <i>Journal of Urology</i> , 2008, 180, 742-748.	0.4	84
53	Intravesical Botulinum Toxin A Administration Inhibits COX-2 and EP4 Expression and Suppresses Bladder Hyperactivity in Cyclophosphamide-Induced Cystitis in Rats. <i>European Urology</i> , 2009, 56, 159-167.	1.9	84
54	Urethral Dysfunction in Diabetic Rats. <i>Journal of Urology</i> , 2004, 171, 1959-1964.	0.4	81

#	ARTICLE	IF	CITATIONS
55	The Application of Botulinum Toxin in the Prostate. <i>Journal of Urology</i> , 2006, 176, 2375-2382.	0.4	80
56	The overactive bladder progression to underactive bladder hypothesis. <i>International Urology and Nephrology</i> , 2014, 46, 23-27.	1.4	76
57	Multiplex Analysis of Urinary Cytokine Levels in Rat Model of Cyclophosphamide-induced Cystitis. <i>Urology</i> , 2009, 73, 421-426.	1.0	75
58	Myoblast therapy for stress urinary incontinence and bladder dysfunction. <i>World Journal of Urology</i> , 2000, 18, 56-61.	2.2	67
59	Passive Biaxial Mechanical Properties of the Rat Bladder Wall After Spinal Cord Injury. <i>Journal of Urology</i> , 2002, 167, 2247-2252.	0.4	67
60	Intraprostatic Capsaicin Injection as a Novel Model for Nonbacterial Prostatitis and Effects of Botulinum Toxin A. <i>European Urology</i> , 2007, 51, 1119-1127.	1.9	67
61	Urodynamic and Immunohistochemical Evaluation of Intravesical Capsaicin Delivery Using Thermosensitive Hydrogel and Liposomes. <i>Journal of Urology</i> , 2004, 171, 483-489.	0.4	65
62	Investigations into the presence of functional α_1 , α_2 and α_3 -adrenoceptors in urothelium and detrusor of human bladder. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2009, 35, 76-83.	1.5	64
63	Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. <i>Brain Research Bulletin</i> , 2003, 61, 165-171.	3.0	62
64	Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium. <i>Neurourology and Urodynamics</i> , 2015, 34, 79-84.	1.5	61
65	Autologous Primary Muscle-Derived Cells Transfer into the Lower Urinary Tract. <i>Tissue Engineering</i> , 2001, 7, 395-404.	4.6	58
66	Role of noradrenergic pathways in sneeze-induced urethral continence reflex in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 292, F639-F646.	2.7	58
67	Nerve growth factor level in the prostatic fluid of patients with chronic prostatitis/chronic pelvic pain syndrome is correlated with symptom severity and response to treatment. <i>BJU International</i> , 2011, 108, 248-251.	2.5	55
68	Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. <i>BJU International</i> , 2008, 102, 080516035452788-???	2.5	54
69	Pathophysiology and animal modeling of underactive bladder. <i>International Urology and Nephrology</i> , 2014, 46, 11-21.	1.4	54
70	Simplified Bladder Botulinum-Toxin Delivery Technique Using Flexible Cystoscope and 10 Sites of Injection. <i>Journal of Endourology</i> , 2005, 19, 880-882.	2.1	53
71	Detrusor overactivity induced by intravesical application of adenosine 5'-triphosphate under different delivery conditions in rats. <i>Urology</i> , 2005, 66, 1332-1337.	1.0	53
72	COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC). <i>Medical Hypotheses</i> , 2020, 145, 110375.	1.5	52

#	ARTICLE	IF	CITATIONS
73	Functional Analysis of Active Urethral Closure Mechanisms Under Sneeze Induced Stress Condition in a Rat Model of Birth Trauma. <i>Journal of Urology</i> , 2006, 176, 2711-2715.	0.4	50
74	Bladder botulinum toxin A injection can benefit patients with radiation and chemical cystitis. <i>BJU International</i> , 2008, 102, 704-706.	2.5	50
75	Future Direction in Pharmacotherapy for Non-neurogenic Male Lower Urinary Tract Symptoms. <i>European Urology</i> , 2013, 64, 610-621.	1.9	50
76	Rapid Detection of Zika Virus in Urine Samples and Infected Mosquitos by Reverse Transcription-Loop-Mediated Isothermal Amplification. <i>Scientific Reports</i> , 2018, 8, 3803.	3.3	50
77	Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: Results of a 12-week, multicenter, open-label, flexible-dose study. <i>Clinical Therapeutics</i> , 2008, 30, 1766-1781.	2.5	49
78	Intravesical drug delivery for dysfunctional bladder. <i>International Journal of Urology</i> , 2013, 20, 552-562.	1.0	48
79	Down-Regulation of Nerve Growth Factor Expression in the Bladder by Antisense Oligonucleotides as New Treatment for Overactive Bladder. <i>Journal of Urology</i> , 2013, 190, 757-764.	0.4	47
80	OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity. <i>Neurology</i> , 2013, 81, 841-848.	1.1	47
81	Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root Ganglia. <i>Journal of Urology</i> , 2002, 168, 1259-64.	0.4	47
82	Recent advances in the neurophysiology of stress urinary incontinence. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 21-24.	1.4	46
83	Association of inflammaging (inflammation+Â+Âaging) with higher prevalence of OAB in elderly population. <i>International Urology and Nephrology</i> , 2014, 46, 871-877.	1.4	45
84	Case for Pharmacotherapy Development for Underactive Bladder. <i>Urology</i> , 2008, 72, 966-967.	1.0	42
85	Epidemiology and demographics of the underactive bladder: a cross-sectional survey. <i>International Urology and Nephrology</i> , 2014, 46, 7-10.	1.4	42
86	Mirabegron: a safety review. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 287-294.	2.4	41
87	Modeling and Treatment of Radiation Cystitis. <i>Urology</i> , 2016, 88, 14-21.	1.0	41
88	Urodynamic monitoring during percutaneous sacral nerve neurostimulation in patients with neurogenic detrusor hyperreflexia. <i>Neurourology and Urodynamics</i> , 2001, 20, 61-71.	1.5	40
89	Development of cellular therapy for the treatment of stress urinary incontinence. <i>International Urogynecology Journal</i> , 2011, 22, 1075-1083.	1.4	40
90	Intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder: pilot study. <i>International Urology and Nephrology</i> , 2015, 47, 465-467.	1.4	40

#	ARTICLE	IF	CITATIONS
91	Diabetes-induced Alterations in Biomechanical Properties of Urinary Bladder Wall in Rats. <i>Urology</i> , 2009, 73, 911-915.	1.0	39
92	Development and Validation of the Actionable Bladder Symptom Screening Tool for Multiple Sclerosis Patients. <i>International Journal of MS Care</i> , 2013, 15, 182-192.	1.0	39
93	Intravesical Liposomal Tacrolimus Protects against Radiation Cystitis Induced by 3-Beam Targeted Bladder Radiation. <i>Journal of Urology</i> , 2015, 194, 578-584.	0.4	38
94	Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study. <i>International Urology and Nephrology</i> , 2016, 48, 1029-1036.	1.4	37
95	A double-blind, randomized, placebo-controlled clinical trial evaluating the safety and efficacy of autologous muscle derived cells in female subjects with stress urinary incontinence. <i>International Urology and Nephrology</i> , 2018, 50, 2153-2165.	1.4	37
96	1 ^α -ADRENERGIC MECHANISM IN DIABETIC URETHRAL DYSFUNCTION IN RATS. <i>Journal of Urology</i> , 2005, 173, 1027-1032.	0.4	36
97	The Overactive Bladder: Epidemiology and Morbidity. <i>Urologic Clinics of North America</i> , 2006, 33, 433-438.	1.8	36
98	Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. <i>Neurourology and Urodynamics</i> , 2011, 30, 421-427.	1.5	36
99	Liposomal bladder instillations for IC/BPS: an open-label clinical evaluation. <i>International Urology and Nephrology</i> , 2014, 46, 2291-2295.	1.4	36
100	DEVELOPMENT OF NONINVASIVE VELOCITY FLOW VIDEO URODYNAMICS USING DOPPLER SONOGRAPHY. PART II: CLINICAL APPLICATION IN BLADDER OUTLET OBSTRUCTION. <i>Journal of Urology</i> , 1998, 160, 1792-1796.	0.4	35
101	Effect of cryoinjury on the contractile parameters of bladder strips: A model of impaired detrusor contractility. <i>Brain Research Bulletin</i> , 2002, 59, 23-28.	3.0	34
102	De Novo Urinary Symptoms Associated With COVID-19: COVID-19-Associated Cystitis. <i>Journal of Clinical Medicine Research</i> , 2020, 12, 681-682.	1.2	34
103	Functional and Molecular Characterization of Hyposensitive Underactive Bladder Tissue and Urine in Streptozotocin-Induced Diabetic Rat. <i>PLoS ONE</i> , 2014, 9, e102644.	2.5	33
104	Bladder Uptake of Liposomes after Intravesical Administration Occurs by Endocytosis. <i>PLoS ONE</i> , 2015, 10, e0122766.	2.5	33
105	Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. <i>BJU International</i> , 2012, 110, 401-407.	2.5	32
106	Addressing challenges in underactive bladder: recommendations and insights from the Congress on Underactive Bladder (CURE-UAB). <i>International Urology and Nephrology</i> , 2017, 49, 777-785.	1.4	32
107	Urinary Nerve Growth Factor Levels in Urinary Tract Diseases With or Without Frequency Urgency Symptoms. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2010, 2, 88-94.	1.3	31
108	Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions. <i>Toxicon</i> , 2013, 67, 129-140.	1.6	30

#	ARTICLE	IF	CITATIONS
109	Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS). <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 555-570.	2.4	28
110	Modeling of chronic radiation-induced cystitis in mice. <i>Advances in Radiation Oncology</i> , 2016, 1, 333-343.	1.2	28
111	Botulinum toxin for the lower urinary tract. <i>BJU International</i> , 2010, 105, 1046-1058.	2.5	27
112	Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis/bladder pain syndrome—A prospective, multicenter, randomized, double-blind, placebo-controlled study. <i>Neurourology and Urodynamics</i> , 2020, 39, 1505-1514.	1.5	27
113	Neural Mechanisms Underlying Lower Urinary Tract Dysfunction. <i>Korean Journal of Urology</i> , 2014, 55, 81.	1.2	26
114	Urinary nerve growth factor level is correlated with the severity of neurological impairment in patients with cerebrovascular accident. <i>BJU International</i> , 2009, 104, 1158-1162.	2.5	25
115	Development of Potential Orphan Drug Therapy of Intravesical Liposomal Tacrolimus for Hemorrhagic Cystitis Due to Increased Local Drug Exposure. <i>Journal of Urology</i> , 2013, 189, 1553-1558.	0.4	25
116	Liposome Based Intravesical Therapy Targeting Nerve Growth Factor Ameliorates Bladder Hypersensitivity in Rats with Experimental Colitis. <i>Journal of Urology</i> , 2016, 195, 1920-1926.	0.4	25
117	Cancer survivorship issues with radiation and hemorrhagic cystitis in gynecological malignancies. <i>International Urology and Nephrology</i> , 2018, 50, 1745-1751.	1.4	25
118	Potential Effect of Liposomes and Liposome-Encapsulated Botulinum Toxin and Tacrolimus in the Treatment of Bladder Dysfunction. <i>Toxins</i> , 2016, 8, 81.	3.4	24
119	Elevated CXC chemokines in urine noninvasively discriminate OAB from UTI. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F548-F554.	2.7	24
120	Role of the Anterior Cingulate Cortex in the Control of Micturition Reflex in a Rat Model of Parkinson's Disease. <i>Journal of Urology</i> , 2016, 195, 1613-1620.	0.4	24
121	DEVELOPMENT OF NONINVASIVE VELOCITY FLOW VIDEO URODYNAMICS USING DOPPLER SONOGRAPHY. PART I: EXPERIMENTAL URETHRA. <i>Journal of Urology</i> , 1998, 160, 1787-1791.	0.4	23
122	Recent advances in imaging and understanding interstitial cystitis. <i>F1000Research</i> , 2018, 7, 1771.	1.6	23
123	Human muscle-derived cell injection in a rat model of stress urinary incontinence. <i>Muscle and Nerve</i> , 2007, 36, 391-393.	2.2	22
124	Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of tiroprium chloride extended release. <i>Neurourology and Urodynamics</i> , 2010, 29, 551-554.	1.5	22
125	Health Resource Utilization and Cost for Patients with Incontinent Overactive Bladder Treated with Anticholinergics. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 406-413.	0.9	22
126	Advantage of urine based molecular diagnosis of Zika virus. <i>International Urology and Nephrology</i> , 2016, 48, 1961-1966.	1.4	22

#	ARTICLE	IF	CITATIONS
127	Patient characteristics for different therapeutic strategies in the management ketamine cystitis. <i>Neurourology and Urodynamics</i> , 2017, 36, 687-691.	1.5	22
128	Physiology and Pharmacology of the Bladder and Urethra. , 2012, , 1786-1833.e17.		22
129	Association of overactive bladder and stress urinary incontinence in rats with pudendal nerve ligation injury. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008, 294, R1510-R1516.	1.8	21
130	Time-Dependent Alterations of Select Genes in Streptozotocin-Induced Diabetic Rat Bladder. <i>Urology</i> , 2008, 71, 1214-1219.	1.0	20
131	Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. <i>International Urology and Nephrology</i> , 2010, 42, 383-391.	1.4	20
132	Innovative use of intravesical tacrolimus for hemorrhagic radiation cystitis. <i>International Urology and Nephrology</i> , 2015, 47, 1679-1681.	1.4	19
133	A cross-sectional study in the USA of the epidemiology and quality of life of underactive bladder symptoms. <i>International Urology and Nephrology</i> , 2016, 48, 1797-1802.	1.4	19
134	Advances in Therapeutic Development for Radiation Cystitis. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2014, 6, 1-10.	1.3	18
135	Underactive Bladder in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2015, 31, 523-533.	2.6	18
136	Low Energy Shock Wave Therapy Inhibits Inflammatory Molecules and Suppresses Prostatic Pain and Hypersensitivity in a Capsaicin Induced Prostatitis Model in Rats. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4777.	4.1	18
137	Development of an interstitial cystitis risk score for bladder permeability. <i>PLoS ONE</i> , 2017, 12, e0185686.	2.5	18
138	Long COVID and COVID-19-associated cystitis (CAC). <i>International Urology and Nephrology</i> , 2022, 54, 17-21.	1.4	18
139	Physiological effects of human muscle-derived stem cell implantation on urethral smooth muscle function. <i>International Urogynecology Journal</i> , 2008, 19, 1229-1234.	1.4	17
140	Radiation cystitis modeling: A comparative study of bladder fibrosis radio-sensitivity in C57BL/6, C3H, and BALB/c mice. <i>Physiological Reports</i> , 2020, 8, e14377.	1.7	17
141	Challenges and Opportunities in Radiation-induced Hemorrhagic Cystitis. <i>Reviews in Urology</i> , 2016, 18, 57-65.	0.9	17
142	CURE-UAB: shedding light on the underactive bladder syndrome. <i>International Urology and Nephrology</i> , 2014, 46, 1-1.	1.4	16
143	Advanced therapeutic directions to treat the underactive bladder. <i>International Urology and Nephrology</i> , 2014, 46, 35-44.	1.4	16
144	Use of Botulinum Toxin in Urologic Diseases. <i>Urology</i> , 2016, 91, 21-32.	1.0	16

#	ARTICLE	IF	CITATIONS
145	The promise of stem cell therapy to restore urethral sphincter function. <i>Current Urology Reports</i> , 2007, 8, 373-378.	2.2	14
146	Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2015, 7, 77-83.	1.3	14
147	Pharmacological management of interstitial cystitis /bladder pain syndrome and the role cyclosporine and other immunomodulating drugs play. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 495-505.	3.1	14
148	Urodynamic and molecular characteristics of detrusor underactivity in a rat cryoinjury model and effects of low energy shock wave therapy. <i>Neurourology and Urodynamics</i> , 2018, 37, 708-715.	1.5	14
149	Presence of Cleaved Synaptosomal-Associated Protein-25 and Decrease of Purinergic Receptors P2X3 in the Bladder Urothelium Influence Efficacy of Botulinum Toxin Treatment for Overactive Bladder Syndrome. <i>PLoS ONE</i> , 2015, 10, e0134803.	2.5	14
150	Underactive Bladder; Review of Progress and Impact From the International CURE-UAB Initiative. <i>International Neurourology Journal</i> , 2020, 24, 3-11.	1.2	13
151	Treatment of stress urinary incontinence with duloxetine hydrochloride. <i>Reviews in Urology</i> , 2005, 7, 81-6.	0.9	13
152	Effects of Duloxetine on Urethral Continence Reflex and Bladder Activity in Rats with Cerebral Infarction. <i>Journal of Urology</i> , 2015, 194, 842-847.	0.4	12
153	Bladder overactivity involves overexpression of MicroRNA 132 and nerve growth factor. <i>Life Sciences</i> , 2016, 167, 98-104.	4.3	12
154	Effect of Intravesical Liposome-Based Nerve Growth Factor Antisense Therapy on Bladder Overactivity and Nociception in a Rat Model of Cystitis Induced by Hydrogen Peroxide. <i>Human Gene Therapy</i> , 2017, 28, 598-609.	2.7	12
155	Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 1448-1467.	3.1	12
156	State of the art in intravesical therapy for lower urinary tract symptoms. <i>Reviews in Urology</i> , 2010, 12, e181-9.	0.9	12
157	Intravesical Liposome and Antisense Treatment for Detrusor Overactivity and Interstitial Cystitis/Painful Bladder Syndrome. <i>ISRN Pharmacology</i> , 2014, 2014, 1-12.	1.6	11
158	Botulinum Toxin to Treat Neurogenic Bladder. <i>Seminars in Neurology</i> , 2016, 36, 005-009.	1.4	11
159	Low energy shock wave therapy attenuates mitochondrial dysfunction and improves bladder function in HCl induced cystitis in rats. <i>Biomedical Journal</i> , 2022, 45, 482-490.	3.1	11
160	Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. <i>Geriatrics</i> , 2007, 62, 15-24.	0.3	11
161	Use of botulinum toxin for genitourinary conditions: What is the evidence?. <i>Toxicon</i> , 2015, 107, 141-147.	1.6	10
162	Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity. <i>Neurourology and Urodynamics</i> , 2016, 35, 595-600.	1.5	10

#	ARTICLE	IF	CITATIONS
163	Risk of Urinary Tract Carcinoma among Subjects with Bladder Pain Syndrome/Interstitial Cystitis: A Nationwide Population-Based Study. <i>BioMed Research International</i> , 2018, 2018, 1-7.	1.9	10
164	Improves symptoms and urinary biomarkers in refractory interstitial cystitis/bladder pain syndrome patients randomized to extracorporeal shock wave therapy versus placebo. <i>Scientific Reports</i> , 2021, 11, 7558.	3.3	10
165	Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine. <i>PLoS ONE</i> , 2020, 15, e0241388.	2.5	10
166	Gracilis muscle transposition with electrical stimulation for sphincteric incontinence: a new approach. <i>World Journal of Urology</i> , 1997, 15, 320-328.	2.2	9
167	Proteomic Investigation on Chronic Bladder Irritation in the Rat. <i>Urology</i> , 2008, 71, 536-540.	1.0	9
168	Transabdominal Ultrasound Measurement of Detrusor Wall Thickness in Patients with Overactive Bladder. <i>Tzu Chi Medical Journal</i> , 2009, 21, 129-135.	1.1	9
169	Promise of Urinary Nerve Growth Factor for Assessment of Overactive Bladder Syndrome. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2011, 3, 2-9.	1.3	9
170	EDITORIAL: SHOULD WE BE USING CHILI PEPPER EXTRACTS TO TREAT THE OVERACTIVE BLADDER?. <i>Journal of Urology</i> , 1997, 158, 2097-2097.	0.4	8
171	Gracilis urethromyoplasty – an autologous urinary sphincter for neurologically impaired patients with stress incontinence. <i>Spinal Cord</i> , 1997, 35, 546-549.	1.9	8
172	Pharmacologic and Molecular Characterization of Underactive Bladder Induced by Lumbar Canal Stenosis. <i>Urology</i> , 2015, 85, 1284-1290.	1.0	8
173	Long-term functional change of cryoinjury-induced detrusor underactivity and effects of extracorporeal shock wave therapy in a rat model. <i>International Urology and Nephrology</i> , 2019, 51, 617-626.	1.4	8
174	Proteomic analysis of bladder biopsies from interstitial cystitis/bladder pain syndrome patients with and without Hunner’s lesions reveals differences in expression of inflammatory and structural proteins. <i>BMC Urology</i> , 2020, 20, 180.	1.4	8
175	Anandamide transporter-mediated regulation of the micturition reflex in urethane-anesthetized rats. <i>International Urology and Nephrology</i> , 2016, 48, 1407-1412.	1.4	7
176	New technology assessment and current and upcoming therapies for underactive bladder. <i>Neurourology and Urodynamics</i> , 2018, 37, 2932-2937.	1.5	7
177	Correlation between lumbar skeletal muscle size and urinary incontinence after radical prostatectomy. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2020, 12, 245-252.	1.3	7
178	Voiding defects in acute radiation cystitis driven by urothelial barrier defect through loss of E-cadherin, ZO-1 and Uroplakin III. <i>Scientific Reports</i> , 2021, 11, 19277.	3.3	7
179	Genitourinary tract patent update. <i>Expert Opinion on Therapeutic Patents</i> , 2001, 11, 17-31.	5.0	6
180	Defining and advancing education and conservative therapies of underactive bladder. <i>International Urology and Nephrology</i> , 2014, 46, 29-34.	1.4	6

#	ARTICLE	IF	CITATIONS
181	Optimum Management of Overactive Bladder: Medication vs Botox vs InterStim vs Urgent PC. Urology Practice, 2014, 1, 7-12.	0.5	6
182	Crowdsourcing Disease Biomarker Discovery Research: The IP4IC Study. Journal of Urology, 2018, 199, 1344-1350.	0.4	6
183	Reverse Transcription-Loop-mediated Isothermal Amplification (RT-LAMP) Assay for Zika Virus and Housekeeping Genes in Urine, Serum, and Mosquito Samples. Journal of Visualized Experiments, 2018, , .	0.3	6
184	Improved global response outcome after intradetrusor injection of adult muscle-derived cells for the treatment of underactive bladder. International Urology and Nephrology, 2021, 53, 1331-1338.	1.4	6
185	Urinary Incontinence and Alzheimer's Disease: Insights From Patients and Preclinical Models. Frontiers in Aging Neuroscience, 2021, 13, 777819.	3.4	6
186	In-Vivo Whole Bladder Response to Anticholinergic and Musculotropic Agents in Spinal Cord Injured Rats. Journal of Spinal Cord Medicine, 1997, 20, 31-35.	1.4	5
187	Age-related changes in bladder function with altered angiotensin II receptor mechanisms in rats. Neurourology and Urodynamics, 2016, 35, 908-913.	1.5	5
188	Altered Angiogenic Growth Factors in Urine of Prostate Cancer Survivors With Radiation History and Radiation Cystitis. Urology, 2018, 120, 180-186.	1.0	5
189	Intravesical liposome drug delivery and IC/BPS. Translational Andrology and Urology, 2015, 4, 572-8.	1.4	5
190	OnobotulinumtoxinA Has No Effects on Growth of LNCaP and PC3 Human Prostate Cancer Cells. LUTS: Lower Urinary Tract Symptoms, 2013, 5, 168-172.	1.3	4
191	Use of Botulinum Toxin in the Genitourinary System. Handbook of Experimental Pharmacology, 2019, 263, 171-184.	1.8	4
192	Botulinum Toxin Urethral Sphincter Injection to Restore Bladder Emptying in a Woman With Multiple Sclerosis. International Journal of MS Care, 2002, 4, 70-72.	1.0	4
193	Micturition defects and altered bladder function in the mutant mouse model of aging. American Journal of Clinical and Experimental Urology, 2020, 8, 81-92.	0.4	4
194	A PILOT STUDY OF AAV1/SERCA2a GENE TRANSFER IN THE RAT STRESS URINARY INCONTINENCE MODEL. Journal of Urology, 2008, 179, 534-535.	0.4	3
195	OnabotulinumtoxinA for Overactive Bladder and Urinary Incontinence. Journal of Urology, 2017, 197, S224-S225.	0.4	3
196	Making a Case for Not Prescribing Antimuscarinic Drugs to Treat Overactive Bladder in Older Adults. Journal of Urology, 2019, 201, 676-677.	0.4	3
197	Is behavioral therapy plus antimuscarinic better than drug alone to treat overactive bladder?. Reviews in Urology, 2008, 10, 306-8.	0.9	3
198	Cystometric Changes in Pressure-guided Acute Distension Rat Model of the Underactive Bladder. Chi Medical Journal, 2009, 21, 136-139.	1.1	2

#	ARTICLE	IF	CITATIONS
199	Role of Sarco/Endoplasmic Reticulum Calcium ATPase in Lower Urinary Tract Smooth Muscles. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S50.	1.3	2
200	Bladder Instillation of Liposomes for Bladder Coating and Drug Delivery Platform. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S90.	1.3	2
201	Update in the Use of Botulinum Toxin for the Treatment of Benign Prostatic Hyperplasia/ Lower Urinary Tract Symptoms. Current Bladder Dysfunction Reports, 2013, 8, 174-179.	0.5	2
202	Statins Associated Underactive Bladder. LUTS: Lower Urinary Tract Symptoms, 2014, 6, 124-125.	1.3	2
203	Translation, cross-cultural adaptation and validation of the underactive bladder questionnaire to portuguese. International Urology and Nephrology, 2019, 51, 1329-1334.	1.4	2
204	Normal Micturition. , 0, , 11-21.		2
205	DISCUSSION: RESINIFERATOXIN-PRELIMINARY DATA. BJU International, 2000, 85, 65-65.	2.5	1
206	Neurotoxin Versus Neuromodulation for the Treatment of Refractory Overactive Bladder Syndrome. Tzu Chi Medical Journal, 2008, 20, 109-111.	1.1	1
207	Bladder Botulinum Toxin. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S22.	1.3	1
208	Lower Urinary Tract: Diabetes Mellitus focused on Recent Experimental Results. LUTS: Lower Urinary Tract Symptoms, 2009, 1, S87.	1.3	1
209	Clinical Efficacy and Tolerability of the Nicotinic Channel Modulator Dexmecamylamine in Subjects with Overactive Bladder. Journal of Urology, 2015, 194, 1329-1335.	0.4	1
210	Building momentum toward underactive bladder research and education. International Urology and Nephrology, 2015, 47, 1593-1594.	1.4	1
211	Reply to the letter: Urine based molecular diagnosis of Zika virus by Viroj Wiwanitkit. International Urology and Nephrology, 2016, 48, 2025-2025.	1.4	1
212	Pathophysiology and Animal Modeling of Underactive Bladder. , 2016, , 51-68.		1
213	Leak Point Pressure. , 0, , 46-55.		1
214	Epidemiology and Demographics of Underactive Bladder. , 2016, , 1-11.		1
215	Using social media to crowdsource collection of urine samples during a national pandemic. International Urology and Nephrology, 2022, 54, 493-498.	1.4	1
216	Low Bladder Compliance. , 0, , 56-61.		1

#	ARTICLE	IF	CITATIONS
217	Transdermal Oxybutynin. <i>Drugs and Aging</i> , 2003, 20, 865-866.	2.7	0
218	Pittsburgh experience with lower urinary tract botulinum toxin a injectionmichael. <i>Current Urology Reports</i> , 2005, 6, 235-236.	2.2	0
219	Botulinum: A toxin for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms. <i>Current Prostate Reports</i> , 2006, 4, 75-80.	0.1	0
220	Uroflowmetry. , 0, , 37-45.		0
221	Novel Biomarkers for Diagnosis and Therapeutic Assessment of Overactive Bladder: Urinary Nerve Growth Factor and Detrusor Wall Thickness. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, S59.	1.3	0
222	Muscleâ€derived Stem Cell Therapy for Stress Urinary Incontinence. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, S62.	1.3	0
223	Noninvasive Videourodynamics Using Transperineal Doppler Ultrasonography. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, S80.	1.3	0
224	Biomechanics of Diabetic Bladders. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, S94.	1.3	0
225	Gene Therapy for Neurogenic Erectile Dysfunction. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2009, 1, S44.	1.3	0
226	Neurotoxin Use for Voiding Dysfunction. <i>Current Bladder Dysfunction Reports</i> , 2011, 6, 182-189.	0.5	0
227	Editorial Comment from Dr Chancellor to Periurethral injection of autologous adiposeâ€derived regenerative cells for the treatment of male stress urinary incontinence: Report of three initial cases. <i>International Journal of Urology</i> , 2012, 19, 661-661.	1.0	0
228	Spinal glycine transporter-1 inhibition influences the micturition reflex in urethane-anesthetized rats. <i>International Urology and Nephrology</i> , 2016, 48, 349-354.	1.4	0
229	Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 1495-1495.	0.4	0
230	Recent Developments in Imaging in BPS/IC. <i>Current Bladder Dysfunction Reports</i> , 2019, 14, 301-307.	0.5	0
231	Editorial Comment from Dr Chancellor to Decreased urothelial cytoskeleton and cell proliferation protein expression suggest interstitial cystitis/bladder pain syndrome patients with Hunnerâ€™s lesion and gradeâˆ3 glomerulation might be different from other types of patients. <i>International Journal of Urology</i> , 2021, 28, 832-833.	1.0	0
232	Urologic Applications of Botulium Toxin. <i>Journal of the Korean Continence Society</i> , 2002, 6, 22.	0.1	0
233	New Frontiers in the Treatment of Overactive Bladder. <i>Journal of the Korean Continence Society</i> , 2003, 7, 1.	0.1	0
234	Tissue Engineering to Rebuild the Lower Urinary Tract. <i>Japanese Journal of Urology</i> , 2005, 96, 54-55.	0.1	0

#	ARTICLE	IF	CITATIONS
235	OP-051 è,,Šé«,,æå,,ãf ©ãf fãf^ã«ãšãã,è,,Šé«,,ã,¢ãf%ãf-ãfŠãfãf3Î±1å-å©1ã1/2“é©æ-è--ã©æŽ'ã°;æŠ'ã^qãŠ1æãœ (Neurourology/ŠY		
236	IL4 Botulinum Toxin for LUTS Past, Present and Future(The 97th Annual Meeting of the Japanese) Tj ETQq0 0 0 rgBT,Overlock 10 Tf 50 2 0.1		
237	PP-436 ãf©ãf fãf^æŽ'ã°;åå°,,ã«ã-¾ããªã,galaninã©ã1/21å%2(ç™©è;“ãf»è-Žè«-,ç-ã-98å>žæ-¥æœ-æ³CEã°;ã™“çŠã1ã1/4šç-ã/4š). Jap		
238	Botulinum Toxin Injection for Prostate Disorders. , 2011, , 111-130.		0
239	Overactive Bladder and Idiopathic Detrusor Overactivity. , 2011, , 61-78.		0
240	Surgery for Underactive Bladder Treatment. , 2016, , 135-154.		0
241	Radiation Cystitis Modeling: a Comparative Study of Bladder Radiation-Induced Fibrosis in Different Mouse Strains. FASEB Journal, 2019, 33, 366.1.	0.5	0
242	Diagnosis of incontinence. Reviews in Urology, 2008, 10, 242-3.	0.9	0
243	Best of the 2015 AUA Annual Meeting: Highlights From the 2015 American Urological Association Annual Meeting, May 15-19, 2015, New Orleans, LA. Reviews in Urology, 2015, 17, 179-89.	0.9	0
244	Editorial Comment. Journal of Urology, 2022, , 101097JU0000000000000244301.	0.4	0
245	Title is missing!. , 2020, 15, e0241388.		0
246	Title is missing!. , 2020, 15, e0241388.		0
247	Title is missing!. , 2020, 15, e0241388.		0
248	Title is missing!. , 2020, 15, e0241388.		0
249	Pre-Urodynamic Evaluation. , 0, , 1-10.		0
250	Bladder Outlet Obstruction and Impaired Detrusor Contractility in Women. , 0, , 120-144.		0
251	Genital Prolapse. , 0, , 197-211.		0
252	Sphincteric Incontinence in Men and Other Complications of Prostate Cancer Treatment. , 0, , 212-226.		0

#	ARTICLE	IF	CITATIONS
253	Enterocystoplasty and Neobladder. , 0, , 227-234.		0
254	Cystometry. , 0, , 22-36.		0
255	Pitfalls in Interpretation of Urodynamic Studies. , 0, , 69-82.		0
256	Overactive Bladder. , 0, , 83-95.		0